From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree

Summary: Big Pharma companies have been spending billions of dollars buying other companies lately. However, Roche, a major Swiss drugmaker, is choosing to sit this shopping spree out.

Roche's CEO, Thomas Schinecker, gave three simple reasons for this choice. First, interest rates are very high right now, and the company doesn't want to take on unnecessary debt. Second, Roche doesn't need to panic-buy because they already have 19 new medicines planned to launch by the end of the decade. Finally, they simply refuse to overpay for other companies. Instead of rushing into bad deals, Roche is focusing on its own pipeline, even though they recently had to cancel a few experimental drugs that weren't meeting expectations.

Source: rssapp-fiercebiotech-com URL: fiercebiotech.com/biotech/debt-acceptable-prices-roche-ceo-lists-3-reasons-sitting-out-big-pharma-deal-spree (opens in new tab)